Navigation Links
Carrington Reports on ISO 9001:2000 Inspection at Sabila Industrial in Costa Rica
Date:9/6/2007

- Sabila Industrial Originally Certified ISO in January 2003

- No Incidences of Nonconformance Found for Last Two Years - Auditors Stated, "First Time Any Company They Audited Performed at Such a

High Quality Level"

- Company Dedicated to Quality

IRVING, Texas, Sept. 6 /PRNewswire-FirstCall/ -- Carrington Laboratories, Inc. (Pink Sheets: CARN) today announced that its bulk pharmaceutical manufacturing subsidiary, Sabila Industrial, S.A., located in Liberia, Guanacaste, Costa Rica, has completed an annual ISO 9001:2000 re-certification inspection by the European Union's notified body, AENOR Internacional, S.A.U. of Madrid, Spain.

Mr. Jose Zuniga, Carrington's vice president of operations and manager of South American business, stated, "The Chief Inspector representing AENOR Internacional stated that this is the first time any company audited by his team has performed at such a high quality level that no nonconformances with ISO quality systems have been found over a two-year period. We at Carrington, and in particular Sabila Industrial, are delighted that our quality systems are recognized by an EU's notified body. We credit our frequent quality audits in Costa Rica and at our manufacturing facilities in Texas as key to our success."

Mr. Zuniga added, "Using organic certified plant materials, our Costa Rica plant manufactures the GelSite(R) polymer, the raw material key to the drug and vaccine delivery technology being developed by Carrington's biotech subsidiary DelSite Biotechnologies, Inc. GelSite(R) is used to make the influenza nasal powder vaccine for bird flu (H5N1). Additionally, our corporate site in Texas uses organic methods on its grounds, our Costa Rica farming operation is certified organic, and our raw material Manapol(R) is kosher certified. These certifications and quality systems are not inexpensive, but they show our dedication to quality. These inspection results let our customers and potential customers know that, as a corporation, we are dedicated to developing, implementing, and maintaining the highest quality standards for the protection of those who use our raw materials and finished products."

About Sabila Industrial

Sabila Industrial, S.A. is a wholly owned subsidiary of Carrington Laboratories, Inc. dedicated to producing raw materials for oral care, wound care, and consumer products manufactured by Carrington and GelSite(R) for DelSite Biotechnologies, Inc. All naturally derived polymeric raw materials are produced under the FDA's cGMP standards for use in human drugs. An injectable biologic raw material to treat fibrosarcoma in companion animals is produced by Sabila under USDA biologic regulations. Sabila Industrial, S.A. operates in a duty-free zone with an adjacent farm, Finca Sabila, which is certified organic by an agency of the Costa Rican government and recognized by the USDA and the European Union.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally-occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's DelSite Biotechnologies subsidiary is developing its proprietary GelSite(R) technology designed to provide controlled release of peptide and protein-based drugs. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit http://www.carringtonlabs.com.

Certain statements in this release concerning Carrington may be forward-looking. Actual events will be dependent upon a number of factors and risks including, but not limited to: subsequent changes in plans by the Company's management; delays or problems in formulation, manufacturing, distribution, production and/or launch of new finished products; changes in the regulatory process; changes in market trends; and a number of other factors and risks described from time to time in the Company's filings with the Securities & Exchange Commission.


'/>"/>
SOURCE Carrington Laboratories, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... ... In starting a program to hire college athletes, Catalyst COO ... skill.” , In keeping with this philosophy, the Catalyst an Iowa premix manufacturer recently ... to replicate the practice throughout the company. , “I’ve heard coaches talk on television ...
(Date:2/24/2017)... FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... of a $224K grant from the National Institute of Mental Health (NIMH) for the ... based on Delpor’s PROZOR technology and is expected to deliver therapeutic levels ...
(Date:2/24/2017)... N.J. , Feb. 24, 2017  Driven ... and biotechnology are now the fastest growing categories, ... Specialty Actives in Personal Care: Multi-regional Market ... research and management consulting firm Kline. ... bioprocesses that make them more effective for skin ...
(Date:2/24/2017)... , Feb. 24, 2017  OncoSec Medical Incorporated ... immunotherapies, will host a Key Opinion Leader event to ... an oral and poster presentation at the upcoming 2017 ... The KOL event will be held in-person and via ... EST / 9:00 AM PST at the Lotte New ...
Breaking Biology Technology:
(Date:2/3/2017)... SAN ANTONIO , Feb. 3, 2017  Texas Biomedical ... Dr. Larry Schlesinger as the Institute,s ... of Texas Biomed effective May 31, 2017. He is currently ... and Director of the Center for Microbial Interface Biology at ... Dr. Schlesinger as the new President and CEO of Texas ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, ... on emerging technology, announces the availability of a new report, ... Continue Reading ... ... industrial and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, ...
(Date:1/25/2017)... The Elements of Enterprise Information Security ... of a comprehensive set of business processes and ... identities and providing a secured and documented access ... number of programs opted by enterprises to maintain ... processes and changing policies. However, there are some ...
Breaking Biology News(10 mins):